These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33 related articles for article (PubMed ID: 19291500)
1. Effect of Memantine in Chronic Poststroke Aphasia: A Clinical Vignette. Gawande SR; Joshi AD; Jhaveri RH; Acharya A Am J Phys Med Rehabil; 2024 Jun; 103(6):e74-e76. PubMed ID: 38320236 [No Abstract] [Full Text] [Related]
2. Memantine (Namenda) for moderate to severe Alzheimer's disease. Ables AZ Am Fam Physician; 2004 Mar; 69(6):1491-2. PubMed ID: 15053415 [No Abstract] [Full Text] [Related]
3. Molecule of the month. Memantine hydrochloride. Drug News Perspect; 2003; 16(1):55. PubMed ID: 12682671 [No Abstract] [Full Text] [Related]
4. [Little behavior improvement with memantine]. Potz-Biedermann C Med Monatsschr Pharm; 2005 Nov; 28(11):413-4. PubMed ID: 16309030 [No Abstract] [Full Text] [Related]
5. FDA approves memantine drug for treating AD. Am J Alzheimers Dis Other Demen; 2003; 18(6):329-30. PubMed ID: 14682078 [No Abstract] [Full Text] [Related]
6. Memantine in the treatment of dementia. Maggiore C; Locatelli L; Grandi FC; Pizzolato G; Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774 [No Abstract] [Full Text] [Related]
7. Memantine (Namenda, Forest Pharmaceuticals). Roman MW Issues Ment Health Nurs; 2009 Mar; 30(3):202. PubMed ID: 19291500 [No Abstract] [Full Text] [Related]
8. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Grossberg GT; Pejović V; Miller ML; Graham SM Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105 [TBL] [Abstract][Full Text] [Related]
9. Discontinuing Alzheimer's disease drug therapy: why, when, and how. Crutchfield D Director; 2008; 16(1):19-21. PubMed ID: 19343870 [TBL] [Abstract][Full Text] [Related]
10. [Cognitive reserve, cognitive impairment and possibilities of their pharmacological correction]. Kamchatnov PR Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(3):87-91. PubMed ID: 24795927 [No Abstract] [Full Text] [Related]
11. Neuroprotection: extrapolating from neurologic diseases to the eye. Danesh-Meyer HV; Levin LA Am J Ophthalmol; 2009 Aug; 148(2):186-191.e2. PubMed ID: 19464671 [TBL] [Abstract][Full Text] [Related]
12. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]. Franke AG; Lieb K; Fellgiebel A Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422 [TBL] [Abstract][Full Text] [Related]